The Fox Chase Chemical Diversity Center Announces it is Working Together With the Wistar Institute to Discover Inhibitors of Epstein Barr Nuclear Antigen EBNA1 for the Treatment of Epstein Barr Virus-Mediated Cancers
Doylestown, PA. May 20, 2015- FCCDC is pleased to announce that it is working together with the Wistar Institute to discover inhibitors of Epstein Barr Nuclear Antigen EBNA1 for the treatment of Epstein Barr Virus-mediated cancers, funded by the Wellcome Trust, as summarized here.